CL2012002038A1 - Metodo para reducir la presion intraocular que comprende la administracion en forma topica de una composicion farmaceutica que comprende 4-bromo-5-(2-imidazolin-2-ilamin)benzimidazol, en donde el ojo afectado tiene una presion intraocular inferior a la de la linea base; y articulo de elaboracion que comprende a dicha composicion. - Google Patents

Metodo para reducir la presion intraocular que comprende la administracion en forma topica de una composicion farmaceutica que comprende 4-bromo-5-(2-imidazolin-2-ilamin)benzimidazol, en donde el ojo afectado tiene una presion intraocular inferior a la de la linea base; y articulo de elaboracion que comprende a dicha composicion.

Info

Publication number
CL2012002038A1
CL2012002038A1 CL2012002038A CL2012002038A CL2012002038A1 CL 2012002038 A1 CL2012002038 A1 CL 2012002038A1 CL 2012002038 A CL2012002038 A CL 2012002038A CL 2012002038 A CL2012002038 A CL 2012002038A CL 2012002038 A1 CL2012002038 A1 CL 2012002038A1
Authority
CL
Chile
Prior art keywords
intraocular pressure
composition
ylamin
imidazolin
elaboration
Prior art date
Application number
CL2012002038A
Other languages
English (en)
Spanish (es)
Inventor
John E Donello
Daniel W Gil
Mohammed I Dibas
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44169074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012002038(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2012002038A1 publication Critical patent/CL2012002038A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2012002038A 2010-01-21 2012-07-20 Metodo para reducir la presion intraocular que comprende la administracion en forma topica de una composicion farmaceutica que comprende 4-bromo-5-(2-imidazolin-2-ilamin)benzimidazol, en donde el ojo afectado tiene una presion intraocular inferior a la de la linea base; y articulo de elaboracion que comprende a dicha composicion. CL2012002038A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29691210P 2010-01-21 2010-01-21

Publications (1)

Publication Number Publication Date
CL2012002038A1 true CL2012002038A1 (es) 2012-11-16

Family

ID=44169074

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002038A CL2012002038A1 (es) 2010-01-21 2012-07-20 Metodo para reducir la presion intraocular que comprende la administracion en forma topica de una composicion farmaceutica que comprende 4-bromo-5-(2-imidazolin-2-ilamin)benzimidazol, en donde el ojo afectado tiene una presion intraocular inferior a la de la linea base; y articulo de elaboracion que comprende a dicha composicion.

Country Status (17)

Country Link
US (1) US9889088B2 (enExample)
EP (1) EP2525793B1 (enExample)
JP (3) JP2013518051A (enExample)
KR (1) KR20120125305A (enExample)
CN (1) CN102770135A (enExample)
AU (1) AU2011207301A1 (enExample)
BR (1) BR112012018154A2 (enExample)
CA (1) CA2787573A1 (enExample)
CL (1) CL2012002038A1 (enExample)
CO (1) CO6592108A2 (enExample)
IL (1) IL221030A0 (enExample)
MX (1) MX2012008516A (enExample)
RU (1) RU2012134065A (enExample)
SG (1) SG182637A1 (enExample)
TW (1) TW201141477A (enExample)
WO (1) WO2011091225A2 (enExample)
ZA (1) ZA201205470B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130046003A1 (en) * 2011-07-22 2013-02-21 Mohammed I. Dibas Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases
WO2013016072A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
BR112014001501A2 (pt) * 2011-07-22 2017-02-14 Allergan Inc moduladores alfa-2 adrenérgicos para tratamento de distúrbios visuais mediados por projeções visuais centrais do olho
WO2014159576A1 (en) * 2013-03-14 2014-10-02 Allergan, Inc. Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes
TWI699205B (zh) * 2014-12-12 2020-07-21 日商興和股份有限公司 用於預防或治療青光眼之藥物療法
WO2019004080A1 (ja) 2017-06-27 2019-01-03 国立大学法人東京大学 融合遺伝子及び／又はエクソンスキッピングにより生ずる転写産物を検出するためのプローブ及び方法
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
PT4236932T (pt) * 2020-11-02 2026-02-23 Visus Therapeutics Inc Composto degradante num medicamento
WO2023086878A1 (en) * 2021-11-10 2023-05-19 Visus Therapeutics, Inc. Carbachol formulations to enhance anti-presbyopia effects

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
AU704972B2 (en) * 1994-08-04 1999-05-13 H. Lundbeck A/S Novel benzimidazole derivatives
US6495583B1 (en) * 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
CA2603044A1 (en) * 2005-06-29 2007-01-11 Allergan, Inc. Alpha-2 adrenergic agonists for the treatment of pain
CA2641501A1 (en) 2006-02-06 2007-08-16 Nicox S.A. Nitrooxy-comprising derivatives of apraclonidine and brimodnidine as al pha2 -adrenergic receptor agonists
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration

Also Published As

Publication number Publication date
SG182637A1 (en) 2012-08-30
ZA201205470B (en) 2013-05-29
CA2787573A1 (en) 2011-07-28
WO2011091225A3 (en) 2012-05-18
JP6466504B2 (ja) 2019-02-06
CO6592108A2 (es) 2013-01-02
JP2013518051A (ja) 2013-05-20
KR20120125305A (ko) 2012-11-14
US9889088B2 (en) 2018-02-13
JP2017125074A (ja) 2017-07-20
BR112012018154A2 (pt) 2016-04-05
AU2011207301A1 (en) 2012-08-09
TW201141477A (en) 2011-12-01
EP2525793A2 (en) 2012-11-28
WO2011091225A2 (en) 2011-07-28
IL221030A0 (en) 2012-09-24
US20110178145A1 (en) 2011-07-21
CN102770135A (zh) 2012-11-07
JP2016026206A (ja) 2016-02-12
MX2012008516A (es) 2012-10-15
RU2012134065A (ru) 2014-02-27
EP2525793B1 (en) 2018-09-05

Similar Documents

Publication Publication Date Title
ECSP13012393A (es) Un agente de sostén
AR089339A1 (es) Articulos para fumar, y otros articulos con emanacion de flujo
FI20116138A7 (fi) Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen
AR112286A2 (es) Sistema polimérico de lágrimas artificiales
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
DOP2012000245A (es) Composiciones sólidas
UY34804A (es) Inhibidores del nampt
MX338015B (es) Composiciones que comprenden un componente de estabilidad de la vida util.
BR112017023516A2 (pt) composição de polímero reforçado com fibra, e, artigo.
UA118558C2 (uk) Пептидна сполука
MX2013000201A (es) Metodos para suministrar un activo de atencion sanitaria por medio de administrar articulos de cuidado personal que comprenden un filamento.
CL2012002695A1 (es) Articulo para fumar, que comprende una primera parte que contiene una fuente de material para fumar y una segunda parte que tiene al menos un extremo que esta configurado para desplazarse en relacion con la primera parte, en donde el articulo ademas comprende un agente modificador de humo que se libera en el articulo para fumar; y envase.
CR11369A (es) Anticuerpo anti-glipican-3 que tiene cineticas mejoradas en el plasma
MX2020003515A (es) Laminados elasticos con elasticos curvos y metodos para la fabricacion.
MX2015008069A (es) Conjunto de envasado para dispositivos de administracion de farmacos.
UA110103C2 (uk) Модифікований туберкульозний антиген
DOP2015000006A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
MX2013012000A (es) Composicion y metodo para formar una superficie auto-descontaminante.
CL2015002304A1 (es) Formas del metil {4,6-diamino-2- [1- (2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato
CO6900149A2 (es) Una composición farmacéutica que comprende los fitocanabinoides canabidivarina (cbdv) y canabidiol (cbd)
CR20170314A (es) Formulación de relación fija de insulina glargina/lixisenatida
PE20151435A1 (es) Laquinimod para reducir el dano talamico en la esclerosis multiple
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
HRP20130082A2 (hr) Farmaceutski pripravak za produljeno oslobađanje trimetazidina
MX2019005557A (es) Composicion para el cuidado bucal.